| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Wednesday, July 25, 2018 Forget the speculation you’ve heard over the past few days: GlaxoSmithKline is sticking with its three-unit structure, CEO Emma Walmsley says. And it’s rolling out a cost-cutting plan to make sure all three businesses have the funds they need. |
|
|
| This week's sponsor is Rho. | | | [Webinar] Understanding New Drug Applications (NDAs)
Tuesday, August 14 | 1pm ET / 10am PT
Understand what is involved in an NDA including regulatory strategy, data integration and readiness, and electronic publishing, and get tips that can help you avoid common pitfalls in the submissions process. Register Now! |
Top Stories Of The Week Wednesday, July 25, 2018 GlaxoSmithKline has made a $300 million equity investment in 23andMe as part of a deal that pulls it close to the consumer genetics pioneer. The partners are contributing preclinical programs to a 50-50 collaboration that will use 23andMe’s genotypic and phenotypic data to accelerate progress. Monday, July 23, 2018 Bristol-Myers Squibb is locked in some pretty big marketing battles—but it’ll have to soldier on without its commercial leader. On Monday, the New Jersey drugmaker said EVP and Chief Commercial Officer Murdo Gordon would leave the company in early August to pursue another opportunity. Wednesday, July 25, 2018 GlaxoSmithKline didn’t have much in the way of R&D news during their last quarterly update, but the company told analysts to watch that space during the second quarter, as some big research news was in the offing. Tuesday, July 24, 2018 One of AbbVie’s most highly anticipated pipeline candidates has reached the regulatory finish line. On Tuesday, the FDA approved Orilissa, a treatment for pain associated with endometriosis—and a potential blockbuster contributor to AbbVie's life after Humira biosimilars hit. Wednesday, July 25, 2018 Pharma giant Novartis has signed Shyft, a Medidata Solutions subsidiary, to help strengthen its digital solutions to aid the launch of new therapies targeted for the European market. Monday, July 23, 2018 GLP-1 receptor agonists make up a well-established class of treatment for Type 2 diabetes. Because of their possible actions on nerve cells, scientists are now exploring their use in neurodegenerative diseases, and one biotech company has charted some positive early results. Monday, July 23, 2018 French Big Pharma Sanofi, through its venture arm, has led a $17 million funding round for Click Therapeutics, a startup looking to boost work on an online platform of “prescription digital therapeutics.” Tuesday, July 24, 2018 Pressing ahead with its "mosaic" HIV vaccine, Johnson & Johnson reports that its regimen elicited immune responses that lasted one year after vaccination in phase 1/2a study participants. Monday, July 23, 2018 There is more M&A action in the CDMO arena this week as New Jersey-based Cambrex struck a deal to buy Halo Pharma, picking up two manufacturing facilities in the process. Resources Sponsored by: Veeva Industry Research: See new results from one of the industry's largest, global clinical operations surveys. Sponsored by: Veeva Ready to modernize your RIM environment? Secure buy-in with these tips. Sponsored by: Medidata Accelerate Clinical Research as Study Complexity Grows Sponsored by: Veeva See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs). Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. |
